BONITA SPRINGS, Fla., April 16 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held company developing targeted cancer treatment therapies, today announced the appointment of Pedro Granadillo as Chairman of the company’s Board of Directors. Mr. Granadillo is a highly-respected pharmaceutical industry leader with over 30 years of experience in corporate management.
“Pedro’s appointment as Chairman of the Board of Directors will further expand his leadership role within our company and will play a key role in our partnering efforts and corporate strategy. We are pleased to have such a widely respected and experienced senior pharmaceutical executive chair our Board of Directors,” said Edmundo Muniz, Chief Executive Officer of Tigris. “His past experience and proven track record in pharmaceutical drug development will be instrumental as we drive our partnering programs and our clinical programs forward.”
“I am excited to be serving as Chairman at this important time in the Company’s development,” said Mr. Granadillo. “I look forward to working with the management team, the Board and the Company’s investors in implementing the Company’s strategic initiatives over the next year and beyond.”
Mr. Granadillo served as Senior Vice President for Eli Lilly and Company until his retirement in 2004 after 34 years of service. As a member of Lilly’s Executive Committee and as Lilly’s head of human resources, manufacturing and quality, he was responsible for policies affecting a global workforce of more than 45,000 employees, as well as a broad network of manufacturing facilities for its extensive line of products. Mr. Granadillo led initiatives that brought Lilly wide recognition as a progressive employer. He also oversaw more than 20 sites and 13,000 employees involved in the manufacturing of Lilly’s conventional “small-molecule” pharmaceuticals and “large-molecule” biotech therapies.
Mr. Granadillo also currently serves on the boards of directors of Haemonetics Corporation of Braintree, MA; Noven Pharmaceuticals, Miami, FL; and Nile Therapeutics, San Francisco, CA. Mr. Granadillo earned his B.S. degree in Industrial Engineering from Purdue University.
About Tigris Pharmaceuticals, Inc.
Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies, using a translational research approach, for use in oncology and other areas of unmet medical need. Tigris’ mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients’ needs for safe and effective treatments of human illnesses.
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. All statements, other than statements of historical facts, including statements regarding Tigris’ strategy, future operations, outlook, and plans and objectives of management, are forward-looking statements. We may not actually achieve these plans, intentions or expectations. Various important factors could cause actual results or events to differ materially from these forward-looking statements, including among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our collaborators’ ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies. This information is provided as of the date of this press release and Tigris does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Anne White, Chief Operating Officer for Tigris Pharmaceuticals,
Inc., +1-239-444-5400, info@tigrispharma.com